Article info
PDFClinical and epidemiological research
Extended report
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
- Correspondence to Dr Daniel J Wallace, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; danielwallac{at}gmail.com
Citation
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Publication history
- Received April 5, 2016
- Revised June 30, 2016
- Accepted July 11, 2016
- First published September 26, 2016.
Online issue publication
February 17, 2017
Article Versions
- Previous version (26 September 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/